The results showed that compared with the high ZNF529-AS1 expression group, the low ZNF529-AS1 expression group had a higher immune score (p = 0.38) (Fig. 7E), stromal score (p < 0.01) (Fig. 7F) and ESTIMATE score (p = 0.063) (Fig. 7G) and lower tumour purity (p = 0.063) (Fig. 7H), indicating that ZNF529-AS1 had a good ability to predict the TME components of HCC patients. This evidence concerns the gene ZNF529 and hepatocellular carcinoma.